Rigel Pharmaceuticals (RIGL) Receivables (2013 - 2026)

Rigel Pharmaceuticals' Receivables history runs 13 years deep, the most recent figure standing at $50.9 million for Q1 2026.

• On a quarterly basis, Receivables rose 1566.5% year-over-year to $50.9 million in Q1 2026; TTM through Mar 2026 was $50.9 million, a 1566.5% increase from a year earlier, with the FY2025 full-year figure at $52.7 million, up 26.55% from the prior year.
• Receivables eased to $50.9 million in Q1 2026 per RIGL's latest filing, from $52.7 million in the prior quarter.
• Across five years, Receivables topped out at $52.7 million in Q4 2025 and bottomed at $3.1 million in Q1 2025.
• The 5-year median for Receivables is $28.9 million (2024), against an average of $29.0 million.
• Across the five-year window, Receivables slumped 89.28% in 2022 and soared 1566.5% in 2026, its largest moves.
• Year by year, Receivables stood at $20.0 million in 2022, then jumped by 52.75% to $30.6 million in 2023, then soared by 36.22% to $41.6 million in 2024, then climbed by 26.55% to $52.7 million in 2025, then fell by 3.26% to $50.9 million in 2026.
• Per Business Quant, the three latest RIGL Receivables figures stand at $50.9 million (Q1 2026), $52.7 million (Q4 2025), and $46.0 million (Q3 2025).